ResearcherPeking UniversityActive in the last 2 years

Ran Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1669-3422; OpenAlex author ID A5009746921. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-based chemotherapy on pancreatic cancer cell… First author DOI 10.1007/s13402-023-00856-z ↗
Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity. Co-author DOI 10.1038/s41597-022-01407-1 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wantao Ying · 2 shared papers, 2022–2024 · strength 0.49
- Paper Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity. DOI 10.1038/s41597-022-01407-1 ↗
- Paper Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-base… DOI 10.1007/s13402-023-00856-z ↗
Xiaoyu Li · 1 shared paper, 2024 · strength 0.23
- Paper Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-base… DOI 10.1007/s13402-023-00856-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.